PSI CRO is a contract research organization that manages pivotal Phase II and Phase III clinical trials for pharmaceutical and biotechnology companies. Founded in 1995 and organically grown, the company operates across 58 countries with over 3,200 professionals. It is fully independent and privately owned, positioning itself as the only mid-sized CRO with this structure.
The company's core services span end-to-end trial management, patient enrollment across oncology, hematology, and other therapeutic areas, data-driven feasibility studies, and personalized site support. PSI CRO maintains a 95% repeat and referral rate among clinical trial sites, reflecting its emphasis on consistent delivery and partnership. The organisation has received CRO Leadership Awards for seven consecutive years and commits to running pivotal trials on time.
PSI CRO operates with an explicit mission to serve employees, clients, sites, and vendors as a partner rather than a vendor. The company emphasises quality standards, international collaboration, and cultural diversity within its workforce. Its approach combines operational rigour with relationship-building, particularly through tailored support to individual trial sites.
